Published in Clin Cancer Res on February 09, 2010
Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet (2012) 2.89
MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer (2012) 2.78
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids (2014) 1.81
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76
Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer (2011) 1.73
Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch (2011) 1.72
miR-34: from bench to bedside. Oncotarget (2014) 1.59
Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics (2011) 1.59
Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet (2012) 1.59
MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis (2011) 1.51
Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One (2011) 1.48
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis (2014) 1.32
Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene (2011) 1.29
miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet (2014) 1.25
MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS One (2011) 1.24
MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J Biol Chem (2011) 1.23
MicroRNA Regulation of SIRT1. Front Physiol (2012) 1.21
Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A (2010) 1.20
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat (2011) 1.19
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol (2012) 1.11
Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene (2011) 1.11
The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Front Oncol (2013) 1.08
Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One (2013) 1.06
Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. Am J Pathol (2010) 1.06
MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. Pharmaceuticals (Basel) (2013) 1.04
Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res (2014) 1.01
Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget (2014) 0.99
Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res (2013) 0.99
MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol (2014) 0.98
Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res (2012) 0.98
Regulation of Metastasis by microRNAs in Ovarian Cancer. Front Oncol (2014) 0.97
Blocking and randomization to improve molecular biomarker discovery. Clin Cancer Res (2014) 0.96
Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Onco Targets Ther (2013) 0.96
The tumour suppressor miR-34c targets MET in prostate cancer cells. Br J Cancer (2013) 0.95
microRNA therapies in cancer. Mol Cell Ther (2014) 0.95
MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation. Haematologica (2012) 0.95
Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma. J Exp Clin Cancer Res (2014) 0.94
miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep (2014) 0.94
Minireview: The roles of small RNA pathways in reproductive medicine. Mol Endocrinol (2011) 0.92
Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer (2014) 0.91
MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today (2012) 0.90
MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. Cell Cycle (2011) 0.90
Identification of novel targets for miR-29a using miRNA proteomics. PLoS One (2012) 0.90
Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques (2012) 0.89
Association between miR34b/c polymorphism rs4938723 and cancer risk: a meta-analysis of 11 studies including 6169 cases and 6337 controls. Med Sci Monit (2014) 0.89
MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biol Med (2015) 0.89
Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med (2013) 0.89
Therapeutic use of microRNAs in lung cancer. Biomed Res Int (2014) 0.87
miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Mol Cancer Res (2013) 0.87
Role of the stem cell niche in the pathogenesis of epithelial ovarian cancers. Mol Cell Oncol (2014) 0.86
CD95 is part of a let-7/p53/miR-34 regulatory network. PLoS One (2012) 0.85
Non-coding RNAs and cancer. Int J Mol Sci (2013) 0.85
Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer. Sci Rep (2015) 0.85
Association between DNA methylation in the miR-328 5'-flanking region and inter-individual differences in miR-328 and BCRP expression in human placenta. PLoS One (2013) 0.83
A competitive regulatory mechanism discriminates between juxtaposed splice sites and pri-miRNA structures. Nucleic Acids Res (2013) 0.82
Elevated miR-34c-5p mediates dermal fibroblast senescence by ultraviolet irradiation. Int J Biol Sci (2013) 0.82
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
A long non-coding RNA targets microRNA miR-34a to regulate colon cancer stem cell asymmetric division. Elife (2016) 0.80
miR-34c-3p inhibits cell proliferation, migration and invasion of hepatocellular carcinoma by targeting MARCKS. Int J Clin Exp Pathol (2015) 0.80
The p53-microRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses. Med Hypotheses (2013) 0.80
Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. Epigenetics (2014) 0.80
Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer. Medicine (Baltimore) (2016) 0.79
MicroRNA expression profiling of mature ovarian teratomas. Oncol Lett (2011) 0.79
The orphan nuclear receptor NR4A2 is part of a p53-microRNA-34 network. Sci Rep (2016) 0.78
miR-34a inhibits proliferation and invasion of bladder cancer cells by targeting orphan nuclear receptor HNF4G. Dis Markers (2015) 0.78
A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material. Br J Cancer (2013) 0.78
A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells. Cancer Biol Ther (2012) 0.78
P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy. Mol Cancer (2014) 0.78
MiR-29c regulates the expression of miR-34c and miR-449a by targeting DNA methyltransferase 3a and 3b in nasopharyngeal carcinoma. BMC Cancer (2016) 0.78
Human papillomavirus E6 and E7 oncoproteins affect the expression of cancer-related microRNAs: additional evidence in HPV-induced tumorigenesis. J Cancer Res Clin Oncol (2016) 0.78
The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms? Cancers (Basel) (2014) 0.77
Downregulation of cell cycle-related proteins in ovarian cancer line and cell cycle arrest induced by microRNA. Int J Clin Exp Med (2015) 0.77
Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Elife (2015) 0.77
MicroRNAs in Gynecological Cancers: Small molecules with big implications. Cancer Lett (2017) 0.76
Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells. RNA (2015) 0.76
High-throughput sequencing of pituitary and hypothalamic microRNA transcriptome associated with high rate of egg production. BMC Genomics (2017) 0.75
Multiple functional linear model for association analysis of RNA-seq with imaging. Quant Biol (2015) 0.75
The influence of miR-34a expression on stemness and cytotoxic susceptibility of breast cancer stem cells. Cancer Biol Ther (2016) 0.75
Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer. Yonsei Med J (2017) 0.75
Clinical biomarkers of pulmonary carcinoid tumors in never smokers via profiling miRNA and target mRNA. Cell Biosci (2014) 0.75
Up-regulation of CRKL by microRNA-335 methylation is associated with poor prognosis in gastric cancer. Cancer Cell Int (2017) 0.75
Low expression of microRNA-1908 predicts a poor prognosis for patients with ovarian cancer. Oncol Lett (2017) 0.75
Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis (2017) 0.75
MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. Endocr Relat Cancer (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
The impact of microRNAs on protein output. Nature (2008) 32.39
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res (2005) 29.17
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature (2008) 8.69
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle (2007) 7.00
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 6.20
The miR-34 family in cancer and apoptosis. Cell Death Differ (2009) 5.92
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev (2001) 5.09
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95
RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA (2005) 4.91
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
Systematic discovery and characterization of fly microRNAs using 12 Drosophila genomes. Genome Res (2007) 4.28
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res (2008) 3.81
miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods (2009) 3.03
Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell (2007) 3.02
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett (2008) 2.81
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ (2009) 2.80
Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res (2003) 2.58
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis (2009) 2.41
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (2009) 2.25
MicroRNAs impair MET-mediated invasive growth. Cancer Res (2008) 1.81
Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol (2003) 1.31
Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/- mice. Genes Dev (1996) 1.22
Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol (2008) 0.91
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proc Natl Acad Sci U S A (2003) 8.92
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle (2007) 7.00
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
MicroRNA-34a regulates cardiac ageing and function. Nature (2013) 4.03
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res (2006) 3.58
Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A (2002) 3.55
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle (2011) 3.15
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res (2003) 3.04
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol Cell (2003) 2.90
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature (2013) 2.78
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res (2003) 2.58
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Focus on epithelial ovarian cancer. Cancer Cell (2004) 2.47
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res (2005) 2.37
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
c-kit+ precursors support postinfarction myogenesis in the neonatal, but not adult, heart. Proc Natl Acad Sci U S A (2012) 2.35
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther (2003) 2.27
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res (2006) 2.23
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res (2010) 2.15
Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res (2008) 2.15
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest (2014) 2.01
Immunohistochemical differences between mucinous and microglandular adenocarcinomas of the endometrium and benign endocervical epithelium. Int J Gynecol Pathol (2008) 1.99
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A (2008) 1.97
Improved diagnosis of periprosthetic joint infection by multiplex PCR of sonication fluid from removed implants. J Clin Microbiol (2010) 1.94
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A (2011) 1.90
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development (2010) 1.86